Percutaneous Coronary Intervention

Also known as: PCI

DrugDrug NameDrug Description
DB00054AbciximabAbciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
DB00945Acetylsalicylic acidThe prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
DB06441CangrelorCangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application.
DB00063EptifibatideSynthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation.
DB01109HeparinUnfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
DrugDrug NameTargetType
DB00054AbciximabIntegrin beta-3target
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00054AbciximabComplement C1r subcomponenttarget
DB00054AbciximabComplement C1q subcomponent subunit Atarget
DB00054AbciximabComplement C1q subcomponent subunit Btarget
DB00054AbciximabComplement C1q subcomponent subunit Ctarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00054AbciximabComplement C1s subcomponenttarget
DB00054AbciximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00054AbciximabIntegrin alpha-IIbtarget
DB00054AbciximabVitronectintarget
DB00945Acetylsalicylic acidProstaglandin G/H synthase 1target
DB00945Acetylsalicylic acidProstaglandin G/H synthase 2target
DB00945Acetylsalicylic acidSerum albumincarrier
DB00945Acetylsalicylic acidAldo-keto reductase family 1 member C1target
DB00945Acetylsalicylic acidSolute carrier family 22 member 6transporter
DB00945Acetylsalicylic acidMultidrug resistance protein 1transporter
DB00945Acetylsalicylic acidSolute carrier family 22 member 7transporter
DB00945Acetylsalicylic acidCytochrome P450 2C19enzyme
DB00945Acetylsalicylic acidCytochrome P450 2C8enzyme
DB00945Acetylsalicylic acidCytochrome P450 2C9enzyme
DB00945Acetylsalicylic acid5'-AMP-activated protein kinasetarget
DB00945Acetylsalicylic acidEndothelin-1 receptortarget
DB00945Acetylsalicylic acidInhibitor of nuclear factor kappa-B kinase subunit betatarget
DB00945Acetylsalicylic acidCellular tumor antigen p53target
DB00945Acetylsalicylic acid78 kDa glucose-regulated proteintarget
DB00945Acetylsalicylic acidRibosomal protein S6 kinase alpha-3target
DB00945Acetylsalicylic acidNF-kappa-B inhibitor alphatarget
DB00945Acetylsalicylic acidNuclear factor NF-kappa-Btarget
DB06441CangrelorP2Y purinoceptor 12target
DB00063EptifibatideIntegrin beta-3target
DB01109HeparinAntithrombin-IIItarget
DB01109HeparinCoagulation factor Xtarget
DB01109HeparinP-selectintarget
DB01109HeparinHeparanaseenzyme
DB01109HeparinFibroblast growth factor receptor 4target
DB01109HeparinFibroblast growth factor 4target
DB01109HeparinFibroblast growth factor 19target
DB01109HeparinFibroblast growth factor receptor 1target
DB01109HeparinFibroblast growth factor 1target
DB01109HeparinFibroblast growth factor receptor 2target
DB01109HeparinFibroblast growth factor 2target
DB01109HeparinPlatelet factor 4target
DB01109HeparinHepatocyte growth factortarget
DrugDrug NamePhaseStatusCount
DB09303Evolocumab0Recruiting1
DB12795CMX-20432Completed1
DB00758Clopidogrel2Completed1
DB00758Clopidogrel2Recruiting1
DB00758Clopidogrel2Unknown Status1
DB12955Delparantag2Terminated1
DB06350Elinogrel2Completed1
DB00758Clopidogrel2 / 3Active Not Recruiting1
DB01225Enoxaparin2 / 3Completed1
DB06209Prasugrel2 / 3Active Not Recruiting1
DB08816Ticagrelor2 / 3Active Not Recruiting1
DB00945Acetylsalicylic acid3Completed2
DB00945Acetylsalicylic acid3Terminated1
DB00640Adenosine3Unknown Status1
DB00009Alteplase3Not Yet Recruiting1
DB00006Bivalirudin3Terminated1
DB00758Clopidogrel3Completed2
DB00758Clopidogrel3Terminated1
DB00758Clopidogrel3Unknown Status1
DB06695Dabigatran etexilate3Completed1
DB01109Heparin3Terminated1
DB06209Prasugrel3Completed1
DB06228Rivaroxaban3Completed1
DB04902Ticagrelor3Completed1
DB08816Ticagrelor3Completed2
DB00775Tirofiban3Withdrawn1
DB00682Warfarin3Completed1
DB00945Acetylsalicylic acid4Active Not Recruiting1
DB00945Acetylsalicylic acid4Completed1
DB00945Acetylsalicylic acid4Enrolling by Invitation1
DB00945Acetylsalicylic acid4Not Yet Recruiting1
DB00945Acetylsalicylic acid4Recruiting1
DB00640Adenosine4Not Yet Recruiting1
DB01076Atorvastatin4Enrolling by Invitation1
DB04115Berberine4Not Yet Recruiting1
DB00006Bivalirudin4Completed1
DB06441Cangrelor4Recruiting1
DB01166Cilostazol4Completed1
DB00758Clopidogrel4Completed3
DB00758Clopidogrel4Enrolling by Invitation1
DB00758Clopidogrel4Not Yet Recruiting1
DB00758Clopidogrel4Recruiting1
DB00343Diltiazem4Completed1
DB01225Enoxaparin4Recruiting1
DB00813Fentanyl4Recruiting1
DB01109Heparin4Completed1
DB08947Iopamidol4Not Yet Recruiting1
DB09220Nicorandil4Enrolling by Invitation1
DB00727Nitroglycerin4Completed1
DB01132Pioglitazone4Completed1
DB08860Pitavastatin4Withdrawn1
DB06209Prasugrel4Completed1
DB01098Rosuvastatin4Enrolling by Invitation1
DB08816Ticagrelor4Enrolling by Invitation1
DB08816Ticagrelor4Recruiting2
DB00775Tirofiban4Completed1
DB00661Verapamil4Completed1
DB00945Acetylsalicylic acidNot AvailableRecruiting1
DB00758ClopidogrelNot AvailableCompleted2
DB12362Diaminohydroxypropanetetraacetic acidNot AvailableRecruiting1
DB08816TicagrelorNot AvailableCompleted1